Correlation Between MaxCyte and Design Therapeutics

Can any of the company-specific risk be diversified away by investing in both MaxCyte and Design Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MaxCyte and Design Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between MaxCyte and Design Therapeutics, you can compare the effects of market volatilities on MaxCyte and Design Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MaxCyte with a short position of Design Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of MaxCyte and Design Therapeutics.

Diversification Opportunities for MaxCyte and Design Therapeutics

0.43

Correlation Coefficient

MaxCyte  Design Therapeutics

Very weak diversification

The 3 months correlation between MaxCyte and Design is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding MaxCyte and Design Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Design Therapeutics and MaxCyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MaxCyte are associated (or correlated) with Design Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Design Therapeutics has no effect on the direction of MaxCyte i.e., MaxCyte and Design Therapeutics go up and down completely randomly.

Pair Corralation between MaxCyte and Design Therapeutics

Given the investment horizon of 90 days MaxCyte is expected to under-perform the Design Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, MaxCyte is 1.25 times less risky than Design Therapeutics. The stock trades about -0.1 of its potential returns per unit of risk. The Design Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  436.00  in Design Therapeutics on May 5, 2025 and sell it today you would lose (54.00) from holding Design Therapeutics or give up 12.39% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

MaxCyte  vs.  Design Therapeutics

MaxCyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days MaxCyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in September 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Design Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Design Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with MaxCyte and Design Therapeutics

The main advantage of trading using opposite MaxCyte and Design Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MaxCyte position performs unexpectedly, Design Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will offset losses from the drop in Design Therapeutics' long position.

The idea behind MaxCyte and Design Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.